Seer, Inc. - Class A Common Stock (SEER)

The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Seer, Inc. (“Seer” or “the Company”) (NASDAQ: SEER) for violations of the securities laws.

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group” or “we”), who collectively own approximately 7.7% of the outstanding common stock of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today issued the following statement in response to Chairman and CEO Omid Farokhzad, M.D.’s July 1, 2026 proposal to acquire Seer:

Seer is Delivering Clear Progress Against its Strategic Plan and Maintaining Focus on Cost Discipline, Governance Rigor and Product Innovation 

No Stockholder Action Required at This Time

Seer's particle-based proteomics IP withstands challenges in both Europe and the United States

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group” or “we”), who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today released a presentation detailing the urgent case for boardroom change at Seer.

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group” or “we”), who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today issued the following statement.

Findings from more than 5,500 plasma samples demonstrate the feasibility of combining deep plasma proteomics generated by the Proteograph Product Suite with ID-Free AI approaches across ten major cancer types

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group” or “we”), who collectively own approximately 7.7% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today issued the following statement:

Urges Stockholders to Vote “FOR” ONLY Seer’s Director Nominees on the BLUE Proxy Card

Reinforces Seer’s Clear Strategy, Strong Governance and Significant Long-Term Value Creation Opportunity

Seeks Exclusion Order Barring Importation of Infringing Proteonano Kits and Workstations

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group” or “we”), who collectively own approximately 7.8% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today issued the following open letter to the Company’s independent directors and financial and legal advisors in response to Seer’s apparent bad-faith rejection of the Radoff-JEC Group’s three fully financed proposals to acquire Seer.

Drs. Sang-Won Lee and Jaewoo Kang to share early insights from Seer's 20,000-sample collaboration with Korea University in breakfast symposium on AI-driven multi-cancer screening

REDWOOD CITY, Calif., May 21, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors (the “Board”) has thoroughly reviewed and unanimously rejected the further revised unsolicited non-binding proposal received on May 14, 2026, from Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), to acquire all of the outstanding shares of Seer’s Class A common stock for $2.40 per share in cash plus a contingent value right (the “May 14 Revised Proposal”).

Bradley L. Radoff and Michael Torok, who collectively own approximately 7.8% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (the “Company”), today submitted the following improved non-binding proposal to acquire the Company – their third such proposal – for $2.40 per share in cash plus a contingent value right.

REDWOOD CITY, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial results for the quarter ended March 31, 2026.

Seer defends its pioneering Proteograph® Product Suite intellectual property (IP)

Seasoned life sciences executive brings extensive global commercial leadership to accelerate growth and expand adoption of Seer’s Proteograph® Product Suite

REDWOOD CITY, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the first quarter 2026 on Wednesday, May 13, 2026. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group” or “we”), who collectively own approximately 7.6% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today issued the following statement in response to the Seer Board of Directors’ (the “Board”) rejection of the Radoff-JEC Group’s improved non-binding proposal to acquire the Company for $2.35 per share in cash plus a contingent value right.

Board Determines Proposal Significantly Undervalues Seer and Is Not in the Best Interests of Stockholders

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 7.6% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today submitted the following improved non-binding proposal to acquire the Company for $2.35 per share in cash plus a contingent value right.

No Stockholder Action Required at This Time

Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the “Radoff-JEC Group”), who collectively own approximately 7.6% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) (“Seer” or the “Company”), today submitted the following non-binding proposal to acquire the Company for $2.25 per share in cash plus a contingent value right, and also nominated Howard H. Berman, Joshua S. Horowitz and Luis E. Rinaldini for election to the Board of Directors at the Company’s upcoming 2026 annual meeting of stockholders.